HONG KONG – With an eye on an innovative biologic therapy that fulfills an unmet need in Asia, Shanghai-based biotech Imab purchased the exclusive Asian rights for a potential biologic drug for autoimmune diseases from Swiss company Ferring Pharmaceuticals SA.